Supplementary Table 1Gene mutations in tissue and plasma pre- and post-treatment.

|  |  |  |
| --- | --- | --- |
| Gene mutations | Plasma mutations abundance | Tissue mutations abundance |
| pre-treat | post-treat |  | pre-treat | post-treat | pre-treat | post-treat |
| BRAF | p.V600E (c.T1799A) | BRAF | c.1799T>A (p.V600E) | 0.2% | 0.6% | 20.0% | 13.9% |
| TP53 | p.K120E (c.A358G) | TP53 | c.358A>G (p.K120E) | 0.5% | 0.8% | 34.5% | 28.8% |
| PIK3R1 | c.1354\_1355ins | PIK3R1 | c.1356\_1403dup | 0.1% | 0.4% | 17.6% | 13.1% |
| FH | p.G302C (c.G904T) | LRP1B | c.8980A>G (p.T2994A) | - | - | 2.5% | 1.3% |
|  |  | MLH1 | c.383C>A (p.A128E) |  | - |  | 3.1% |
|  |  | NF2 | c.50A>T (p.K17M) |  | - |  | 3.7% |
|  |  | PDGFRB | c.2168G>A (p.G723E) |  | 0.2% |  | 4.8% |
|  |  | FOXA1 | c.-736\_1062del |  | 0.1% |  | 2.2% |
|  |  | GRM3 | c.2564A>T (p.Q855L) |  | - |  | 3.6% |
|  |  | AR | - |  | - |  | 15.2 times |
| TMB mutations/Mb |  |  |  |  |
| 4.3 | 10.3 |  |  |  |  |